Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 9:2020:8869424.
doi: 10.1155/2020/8869424. eCollection 2020.

A Streamlined Approach to Rapidly Detect SARS-CoV-2 Infection Avoiding RNA Extraction: Workflow Validation

Affiliations

A Streamlined Approach to Rapidly Detect SARS-CoV-2 Infection Avoiding RNA Extraction: Workflow Validation

Catia Mio et al. Dis Markers. .

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly spread worldwide from the beginning of 2020. The presence of viral RNA in samples by nucleic acid (NA) molecular analysis is the only method available to diagnose COVID-19 disease and to assess patients' viral load. Since the demand for laboratory reagents has increased, there has been a worldwide shortage of RNA extraction kits. We, therefore, developed a fast and cost-effective viral genome isolation method that, combined with quantitative RT-PCR assay, detects SARS-CoV-2 RNA in patient samples. The method relies on the addition of Proteinase K followed by a controlled heat-shock incubation and, then, E gene evaluation by RT-qPCR. It was validated for sensitivity, specificity, linearity, reproducibility, and precision. It detects as low as 10 viral copies/sample, is rapid, and has been characterized in 60 COVID-19-infected patients. Compared to automated extraction methods, our pretreatment guarantees the same positivity rate with the advantage of shortening the time of the analysis and reducing its cost. This is a rapid workflow meant to aid the healthcare system in the rapid identification of infected patients, such as during a pathogen-related outbreak. For its intrinsic characteristics, this workflow is suitable for large-scale screenings.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Standard curve made by diluting the SARS-CoV-2-positive control. (a) Shows data from 7 serial dilutions (100%, 20%, 10%, 2%, 1%, 0.5%, and 0.1%) of the SARS-CoV-2-positive control (PC) supplied with the LightMix® Modular kit evaluated with RT-qPCR. The 0.1% dilution showed no amplification curve as NTC. Panel B shows the standard curve made by the 7 dilutions of the PC. NTC: no template control.
Figure 2
Figure 2
Agreement between the in-house method and the gold standard. Bland-Altman's diagram shows the difference between the two methods on the y-axis and their average on the x-axis. The bias between the measurements was 3.16 (CI95% 1.62-4.69) with 95% agreement. The dotted lines represent the bias and the upper and lower limits of 95% agreement.

References

    1. Konrad R., Eberle U., Dangel A., et al. Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020. Eurosurveillance. 2020;25(9) doi: 10.2807/1560-7917.ES.2020.25.9.2000173. - DOI - PMC - PubMed
    1. Wang W., Tang J., Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. Journal of Medical Virology. 2020;92(4):441–447. doi: 10.1002/jmv.25689. - DOI - PMC - PubMed
    1. Helmy Y. A., Fawzy M., Elaswad A., Sobieh A., Kenney S. P., Shehata A. A. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. Journal of Clinical Medicine. 2020;9(4):p. 1225. doi: 10.3390/jcm9041225. - DOI - PMC - PubMed
    1. Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence. Journal of Medical Virology. 2020;92(6):548–551. doi: 10.1002/jmv.25722. - DOI - PMC - PubMed
    1. Rabaan A. A., Al-Ahmed S. H., Haque S., et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Le Infezioni in Medicina. 2020;28(2):174–184. - PubMed

Publication types

MeSH terms